Peptides for Body Recomposition: What the Research Shows

Body recomposition — losing fat and building lean muscle at the same time — is one of the hardest things to pull off in a gym, so it is no surprise that peptides for body recomposition have become something people search for as a shortcut. The pitch is seductive: a small group of compounds that nudge your own body to release more growth hormone and IGF-1, sold with the promise of getting leaner and more muscular at once. This guide takes that pitch seriously and holds it against the actual research — what the human studies measured, where the evidence runs out, and why the honest answer is messier than the marketing. The compounds involved are sold for laboratory research use only, not for human consumption, and are not FDA-approved for physique or performance goals.

What body recomposition actually means

Body recomposition is the process of losing body fat and gaining skeletal muscle at the same time, so your scale weight may barely move while your shape changes. It is difficult because fat loss usually needs an energy deficit while muscle growth usually favors an energy surplus. In controlled research, the combination that reliably produces it is not a peptide at all: a higher-protein diet paired with hard resistance training during a modest calorie deficit has been shown to produce simultaneous lean-mass gain and fat loss, even in already-lean, trained young men. That is the honest benchmark any peptide has to beat.

Which peptides get marketed for body recomposition

The peptides pitched for recomposition cluster into two ideas. The larger group is growth-hormone secretagogues: compounds that signal your pituitary to release more of its own growth hormone rather than supplying any from outside. That group includes GHRH analogs such as CJC-1295, covered in our neutral data sheet at /peptides/cjc-1295, and ghrelin-mimetics such as ipamorelin at /peptides/ipamorelin and the oral compound MK-677 at /peptides/mk-677. The second idea skips the middleman and supplies a growth factor directly: IGF-1 LR3, a modified version of insulin-like growth factor 1, detailed at /peptides/igf-1-lr3. The shared theory is simple — raise growth hormone and IGF-1, and body composition should follow. Whether that theory holds up in people is the whole question, and these remain research-grade compounds that are not FDA-approved for these uses.

What the growth-hormone peptide research actually shows

Start with the part that is real: these compounds can do what they claim to your hormones. In a randomized study of healthy adults, CJC-1295 produced sustained, dose-dependent increases in growth hormone and IGF-1 levels that lasted several days per injection. The catch is what that study did not do — it measured hormone levels, not muscle, fat, or strength. That gap runs through the whole category. Raising a lab marker is a necessary first step for the theory, but it is not the same as the leaner, more muscular body the marketing implies, and for CJC-1295 specifically no controlled trial has carried the story from higher IGF-1 through to a measured change in body composition.

MK-677: the most human data, and the catch

MK-677 (ibutamoren) has the most human data of the group, and it is the most instructive example. In a two-year randomized, placebo-controlled trial in healthy older adults, daily MK-677 raised growth hormone and IGF-1 into a younger-adult range and increased fat-free mass by about one kilogram versus placebo. On the surface that sounds like recomposition. Read the same trial closely, though, and the caveats pile up: there was no significant improvement in muscle strength or physical function, much of the fat-free-mass gain reflected extra body water rather than contractile muscle, and the compound raised fasting blood sugar and reduced insulin sensitivity. In other words, the scale moved without the performance following, and it came with a real metabolic cost.

IGF-1 LR3 and ipamorelin: where the evidence thins out

The other two names people ask about sit on even thinner ground. IGF-1 LR3 is a laboratory-modified form of IGF-1 engineered to stay active far longer than the natural hormone; it is an injectable research chemical with no controlled human trials behind its use for body composition, and our data sheet at /peptides/igf-1-lr3 keeps that framing neutral. Ipamorelin is a selective growth-hormone secretagogue that is popular precisely because it raises growth hormone with fewer off-target effects, but its human body-composition evidence is minimal; most of what circulates about it is mechanism and anecdote rather than trial data, as our ipamorelin data sheet at /peptides/ipamorelin lays out. Neither has the kind of study MK-677 has — which is saying something, given how modest that evidence turned out to be.

Tesamorelin: the one peptide here with a real prescription drug behind it

There is exactly one FDA-approved peptide in this growth-hormone-releasing family, and its story is a useful reality check. Tesamorelin is the active molecule in the FDA-approved prescription drug Egrifta, a growth-hormone-releasing factor indicated to reduce excess abdominal fat in adults with HIV-associated lipodystrophy; in its pivotal trial it reduced visceral fat by roughly 15 percent versus placebo. Two things matter for anyone reading it as a recomposition shortcut. First, its own label states it is not indicated for weight-loss management and is weight-neutral overall — it redistributes a specific kind of fat in a specific medical condition, not physique fat in healthy people. Second, research-grade tesamorelin sold for laboratory use is not the branded drug Egrifta and is not FDA-approved. The same line applies to the GLP-1 weight-loss medicines people mention nearby: semaglutide and tirzepatide are the active molecules in the FDA-approved prescription drugs Wegovy, Ozempic, Zepbound, and Mounjaro for their own approved uses, while research-grade versions are not those drugs and are not FDA-approved.

What the research does not settle

Step back, and a clear pattern emerges. For every peptide marketed for body recomposition, the human evidence either measures hormones instead of physique, shows a change on the scale without a matching gain in strength or function, or does not exist at all. No controlled trial has tested a research-grade peptide for the specific goal of body recomposition in healthy, trained adults — the exact person the marketing targets. Meanwhile the approach that research does support for recomposition is unglamorous and free: progressive resistance training with enough protein, run patiently over months. That is the uncomfortable honest summary of the field. The peptides raise a marker; the training changes the body.

The benefits people chase, and the real cons

To be fair to the category, there are reasons people are curious. Growth-hormone secretagogues are commonly researched for their effect on growth hormone and IGF-1, MK-677 did move fat-free mass in a genuine trial, and users report better sleep and a bigger appetite while using them. But an honest ledger has to include the other column. Reported and studied downsides include water retention and joint puffiness, a sharp rise in appetite, and — with MK-677 specifically — higher blood sugar and reduced insulin sensitivity, which matters for anyone watching their metabolic health. Chronically elevated IGF-1 carries its own theoretical long-term concerns that human trials have not settled. And because these are gray-market research chemicals, purity, potency, and sterility are not verified, so contamination or a mislabeled vial is a genuine, separate risk the studies never measured.

Regulatory status and anti-doping rules

Two status lines belong on every honest version of this topic. On regulation: the research-grade peptides discussed here are not FDA-approved for muscle, fat-loss, or performance goals and are sold for laboratory research use only, not for human consumption — meaning no regulator has confirmed they are safe or effective for these uses. On sport: for anyone competing under anti-doping rules, this whole class is off the table. The World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances at all times under category S2, which explicitly covers growth-hormone-releasing factors and secretagogues like CJC-1295, ipamorelin, and MK-677, as well as IGF-1 and its analogs such as IGF-1 LR3. A WADA-tested athlete should assume every peptide in this guide is bannable.

The bottom line on peptides for body recomposition

Peptides for body recomposition is a story of a big, believable theory sitting on a thin human record. The compounds can raise growth hormone and IGF-1 — that part is real — but raising a marker is not the same as getting leaner and stronger, and the one careful long trial, on MK-677, delivered extra body water and higher blood sugar more than functional recomposition. The single FDA-approved peptide in the family, tesamorelin as Egrifta, is prescribed for a specific HIV-related fat condition and is explicitly not a weight-loss or physique drug, while research-grade versions are not that medicine and are not FDA-approved. If you want the compound-by-compound detail, our neutral data sheets on CJC-1295 at /peptides/cjc-1295, ipamorelin at /peptides/ipamorelin, MK-677 at /peptides/mk-677, and IGF-1 LR3 at /peptides/igf-1-lr3 carry it, and our broader muscle-growth guide at /learn/peptides-for-muscle-growth sets the wider context. The recomposition that research actually supports still comes from the training floor, not a vial.

References & sources

1. Longland TM, et al. Higher compared with lower dietary protein during an energy deficit combined with intense exercise promotes greater lean mass gain and fat mass loss: a randomized trial. American Journal of Clinical Nutrition, 2016;103(3):738-746.
2. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 2006;91(3):799-805.
3. Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of Internal Medicine, 2008;149(9):601-611.
4. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 2007;357(23):2359-2370.
5. U.S. Food and Drug Administration. EGRIFTA SV (tesamorelin) prescribing information: a growth hormone-releasing factor indicated to reduce excess abdominal fat in HIV-infected adults with lipodystrophy; not indicated for weight-loss management. DailyMed, U.S. National Library of Medicine.
6. World Anti-Doping Agency. The Prohibited List: S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics (prohibited at all times), covering GH-releasing factors and secretagogues and IGF-1 and its analogs.